Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Year: 2018
Type: article
Abstract: Background: Ataxia telangiectasia and Rad3-related protein (ATR) is an essential DNA damage response regulator, and is required for proliferating cell survival. DNA-damaging agents often induce replicative stress leading to activation and reliance on ATR; inhibition of ATR signalling is an attractive strategy to sensitize tumors to DNA-damaging chemotherapy. M6620 is a potent, selective inhibitor of ATR with preclinical anticancer activity in combination with DNA-damaging chemotherapy. Here, we report dose expansion cohort data for a phase I trial of M6620 plus Gem in pts with advanced NSCLC (NCT02157792).
Source: Annals of Oncology
Authors: R. Plummer, N. Cook, T. Arkenau, J. Melear, C. Redfern, A.I. Spira, K. Chung, T. Haddad, S.S. Ramalingam, R. Wesolowski, E. Dean, T. Goddemeier, M. Falk, G. Shapiro
Institutions: Freeman Hospital, National Health Service, The Christie NHS Foundation Trust, Sarah Cannon Research Institute, Texas Oncology, Sharp Memorial Hospital, Virginia Cancer Specialists, Prisma Health, Mayo Clinic, Emory University, Winship Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Manchester, Merck KGaA, Darmstadt (Germany), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898339762